Quote:Despite the string of encouraging news about its lead product, NWBO’s share price did not followed suit. Quite the opposite actually—and that is not by chance. Rather, because of Defendants’ spoofing, NWBO’s share price has dropped.
Does it sound familiar?
https://www.cohenmilstein.com/case-study/nort...itigation/
Quote:NWBO completed a 331-patient Phase 3 clinical trial of DCVax-L in the United States, Canada, U.K., and Germany for patients with glioblastoma multiforme (“GBM”), the most aggressive and lethal form of brain cancer. On May 10, 2022, positive top-line results from the clinical trial were presented at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences, showing that DCVax-L had reached both its primary and its secondary endpoints with statistical significance under the Statistical Analysis Plan for the Phase 3 trial. The survival data of the trial was promising; no other GBM trial in decades has shown such improvements in both median survival and the “long tail” of extended survival in both newly diagnosed and recurrent (late stage) GBM patients.
CytoDyn Inc (CYDY) Stock Research Links
Le-Ron-Li-Mab, and they have not.